Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipiodol + ethanol is a therapeutic mixture used primarily for transarterial embolization ablation (TEA) of hepatocellular carcinoma. The combination creates a dual-action treatment where: 1. Lipiodol (ethiodized oil) serves as a radio-opaque carrier that: - Allows visualization of the treatment delivery under fluoroscopy - Selectively accumulates in tumor tissue - Acts as a temporary embolic agent - Serves as a carrier for ethanol 2. Ethanol functions as a strong protein coagulant that: - Directly inactivates tumor cells in situ - Causes vascular endothelial injury and platelet cohesion - Results in permanent occlusion of tumor-feeding vessels - Leads to tumor infarction without causing collateral circulation The mixture is typically injected through the hepatic artery to target liver tumors, with the ratio of Lipiodol to ethanol varying from 1:1 to 5:1 depending on the specific treatment protocol and tumor characteristics[4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lipiodol + ethanol.